Am J Transplant, Volume 22, Suppl 3 Archives - Page 36 of 190 - ATC Abstracts

2022 American Transplant Congress
Evaluation of Compliance and Efficacy with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Tacrolimus in Kidney Transplant Recipients
M. Nikirk¹, J. Chen¹, E. Tillman²
¹Indiana University Health, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN
*Purpose: The purpose of this study is to evaluate compliance and efficacy of The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype guided tacrolimus…
2022 American Transplant Congress
Simultaneous Liver/ Kidney Transplant Reduces Both Donor Specific and Non-Donor Specific HLA Antibodies
X. Zhang, S. Wisel, I. Kim, S. Jordan
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Kidney allografts can be transplanted across strong donor specific antibody (DSA) barriers in simultaneous liver/kidney transplant (SLK) recipients. It is suggested that preformed DSAs…
2022 American Transplant Congress
Dendritic Cell Senescence as a Key Contributor to Transplant Rejection
J. Zhao¹, X. Li¹, S. Jung¹, H. Zhang¹, V. Kasinath¹, J. Azzi¹, P. Sage¹, J. Bromberg², R. Abdi¹
¹Brigham and Women’s Hospital, Boston, MA, ²University of Maryland School of Medicine, Baltimore, MD
*Purpose: Intra-graft inflammation initiated by ischemia-reperfusion injury (IRI) is an unavoidable consequence of transplantation surgery and constitutes a key source of alloimmune responses. IRI leads…
2022 American Transplant Congress
Improving Access and Equity for Transplant: A Single-Center Experience
S. Kodali¹, A. Lopez², C. Egwim², J. Alegria², S. Yi², H. Adrogue², M. Moaddab², H. Huang², I. Hussain², M. Kassi², J. Ontiveros², R. Guardiola², J. Alexander², D. Harvey², K. Maresh², S. Zylicz², L. Loza², J. Corkrean², A. O. Gaber², R. M. Ghobrial¹
¹Sherrie and Alan Conover Center for Liver Disease & Transplantation, Houston Methodist Hospital, Houston, TX, ²Houston Methodist Hospital, Houston, TX
*Purpose: Many Hispanic Americans have misconceptions about transplantation due to language and cultural differences, which can make them less likely to undergo liver transplant (LT)…
2022 American Transplant Congress
Ventricular Modeling Following Bariatric Surgery Decreases Need for Heart Transplantation
R. Choudhury¹, A. Rouhi², G. Hoeltzel³, Y. Bababekov¹, A. Suarez-Pierre⁴, A. Yule¹, N. Vigneshwar⁴, N. Williams⁵, K. Dumon², T. Nydam¹
¹Transplantation Surgery, University of Colorado Hospital, Aurora, CO, ²General Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ³General Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, ⁴Cardiothoracic Surgery, University of Colorado Hospital, Aurora, CO, ⁵General Surgery, Hospital of the University of Pennsylvania, Aurora, CO
*Purpose: For obese patients with congestive heart failure (CHF), aggressive weight loss has been associated with ventricular remodeling. Many have suggested offering bariatric surgery for…
2022 American Transplant Congress
Failure to Account for Social Determinants of Health in Non-HCC MELD Exceptions Exacerbates Geographic Disparities in Access to Liver Transplantation
R. M. Cannon, P. MacLennan, S. S. Sheikh, B. J. Orandi, A. Nasell, J. T. Walker, J. E. Locke
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Non-HCC MELD exceptions have been previously shown to give excess priority for transplant in certain UNOS Regions, but this phenomenon has not been examined…
2022 American Transplant Congress
Liver Transplantation for Patients with Fibrolamellar Hepatocellular Carcinoma: A Comprehensive Multicenter Analysis to Support Future Decision Making
M. P. Claasen¹, T. Ivanics¹, W. G. Polak², J. N. IJzermans², G. Sapisochin¹
¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²HPB and Transplant Surgery, Erasmus MC, Rotterdam, Netherlands
*Purpose: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare tumour accounting for ~1% of all primary liver cancers. Due to its rarity, there is a shortage…
2022 American Transplant Congress
The Paradox of Lifestyle – Related Liver Disease: ASH and NASH
N. Kemmer¹, J. Buggs²
¹Transplant Hepatology, Tampa General Hospital, Tampa, FL, ²Transplant Surgery, Tampa General Hospital, Tampa, FL
*Purpose: In the last decade, the burden of lifestyle-related chronic disease has been on the rise and is considered a growing serious public health concern.…
2022 American Transplant Congress
Circulating Donor-Derived Cell-Free DNA: A Novel Non-Invasive Biomarker for Immune Surveillance in Vascularized Composite Allotransplantation
W. J. Rifkin¹, J. Trilles¹, P. S. Rabbani¹, O. C. Onuh¹, B. E. Gelb², D. J. Ceradini¹, E. D. Rodriguez¹
¹Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, ²Transplant Institute, NYU Langone Health, New York, NY
*Purpose: The purpose of this study is to evaluate whether circulating donor-derived cell-free DNA (dd-cfDNA) could be used as a noninvasive biomarker to detect rejection…
2022 American Transplant Congress
Higher Hepatocellular Carcinoma Tumor Burden Score is Associated with Grater Liver Transplant Survival Benefit
H. Liu¹, W. Zhang², M. Di³, H. Lee⁴, R. Cruz¹, X. Wang², C. Kaltenmeier¹, A. Thompson¹, D. Reddy¹, E. Ashwat¹, M. D'Alesio¹, S. Lebowitz¹, S. Tohme¹, D. Geller¹, A. Tevar¹, C. Hughes¹, A. Humar¹, J. Behari⁵, R. Bataller⁵, S. Hariharan⁵, M. Molinari¹
¹Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Mathematics and Statistics, University of Arkansas at Little Rock, Little Rock, AR, ³Medicine, Medical Oncology, Yale University, New Haven, CT, ⁴Biostatistics, Massachusetts General Hospital, Boston, MA, ⁵Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Liver transplantation(LT) is the best treatment option for early-stage hepatocellular carcinoma(HCC) and cirrhosis. However, patients with various tumor burdens receive identical listing priority, despite…